Trials / Terminated
TerminatedNCT05543252
An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
A Dose-Blinded Extension Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of UCB0599 in Study Participants With Parkinson's Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 428 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 40 Years – 78 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Minzasolmin (UCB0599) | Minzasolmin (UCB0599) Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive minzasolmin (UCB0599) in a pre-specified sequence during the Treatment Period. |
Timeline
- Start date
- 2022-08-29
- Primary completion
- 2025-03-18
- Completion
- 2025-03-25
- First posted
- 2022-09-16
- Last updated
- 2026-04-02
- Results posted
- 2026-04-02
Locations
96 sites across 9 countries: United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05543252. Inclusion in this directory is not an endorsement.